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Abstract 
Purpose  
Neuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine 
and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline 
Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2) respectively. This study 
used immunohistochemistry to evaluate target expression in archival neuroblastoma tissue, 
to determine whether it might facilitate clinical use of molecular radiotherapy. 
Methods  
Tissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from 
patients for whom clinical outcome data were available were sectioned and stained with 
haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2. 
Sections were examined blinded to clinical information and scored for the percentage and 
intensity of tumour cells stained. These data were analysed in conjunction with clinical data. 
Results 
Tissue from 75 patients was examined. Target expression scores varied widely between 
patients: NAT median 45%, inter-quartile range 25% - 65%; and SSTR2 median 55%, 
interquartile range 30% – 80%; and in some cases heterogeneity of expression between 
different parts of a tumour was observed. A weak positive correlation was observed 
between the expression scores of the different targets: correlation coefficient = 0.23, p = 
0.05. MYCN amplified tumours had lower SSTR2 scores: mean difference 23% confidence 
interval 8% - 39%, p < 0.01. Survival did not differ by scores. 
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Conclusions 
As expression of both targets is variable and heterogeneous, imaging assessment of both 
may yield more clinical information than either alone. The clinical value of 
immunohistochemical assessment of target expression requires prospective evaluation.  
Variable target expression within a patient may contribute to treatment failure.  
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Introduction 
 
The childhood cancer neuroblastoma is stratified into low-, intermediate- and high-risk 
groups on the basis of the most powerful prognostic factors: stage, age and molecular 
pathology [1]. Despite sequential advances as a result of innovative multimodality 
treatment protocols [2-5], the prognosis of high-risk neuroblastoma remains poor, with the 
majority of patients dying from refractory or relapsed disease. Attempts to salvage these 
patients often focus on molecular radiotherapy with 131I meta-Iodobenzylguanidine (mIBG) 
[6, 7] or peptide receptor radionuclide therapy with, for example, 177Lu Lutetium DOTATATE 
[8], and a number of clinical trials investigating these treatments are in progress. 
 
Molecular radiotherapy is regarded as a potentially important treatment option for high-risk 
neuroblastoma, because the disease is usually widely disseminated, has a poor prognosis, is 
known to be intrinsically radiosensitive, and, most importantly, expresses a range of specific 
molecular targets, which can be exploited therapeutically. These targets include: the 
noradrenaline transporter molecule (NAT); the somatostatin receptor (SSTR); and the 
diasialoganglioside GD2. 
 
Noradrenaline is a catecholamine produced as a neurotransmitter and a hormone by 
sympathetic nerves and the adrenal medullary cells. NAT is encoded by the SLC6A2 gene [9], 
and is responsible for the active uptake of catecholamines and their analogues such as mIBG 
[10]. Most commonly labelled with 123I, mIBG has an established role in the staging and 
response assessment of neuroblastoma [11, 12]; and there is extensive experience in the 
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use of 131I-mIBG for the treatment of neuroblastoma [6]. While 131I-mIBG molecular 
radiotherapy has been clearly demonstrated to produce responses in a substantial 
proportion of patients with relapsed and refractory neuroblastoma, there have to date been 
no published randomised trials comparing this therapeutic approach with others. One 
randomised trial, however, is ongoing: 131I-mIBG alone versus 131I-mIBG with vincristine and 
irinotecan versus 131I-mIBG with vorinistat (New Approaches to Neuroblastoma Therapy 
Consortium Trial 2011-01, ClinicalTrials.gov identifier NCT02035137). 
 
Somatostatin is a peptide hormone acting on SSTR in target tissues. There are five known 
SSTR subtypes, and SSTR2 is found within various normal tissues [13]. It is often highly 
expressed in neuroblastoma, and to a greater extent than other SSTR subtypes [14, 15]. 
Radiolabelled somatostatin analogues (for example 111In Indium Petetreotide [16] and 68Ga 
Gallium DOTATATE [8]) have been used for the imaging of neuroblastoma and other 
neuroendocrine cancers, and others (for example 90Y Yttrium DOTATOC [17] and 177Lu 
Lutetium DOTATATE [8]) have been used for therapy. A large randomised trial in patients 
with metastatic mid-gut neuroendocrine cancers has demonstrated that molecular 
radiotherapy with 177Lu Lutetium DOTATATE results in significantly better response rates, 
event free survival and mortality compared with a high-dose, long-acting release 
formulation of octreotide alone. A clinical trial in neuroblastoma is ongoing: A phase IIa trial 
of 177-Lutetium DOTATATE in children with primary refractory or relapsed high-risk 
neuroblastoma (EudraCT Number: 2012-000510-10) [18]. 
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Monoclonal antibodies directed against GD2 are an established treatment in the 
immunotherapy of neuroblastoma [4, 19], and radio-labelled versions have been explored 
as potential vectors for molecular radiotherapy [20]. 
 
Selection of patients with neuroblastoma for molecular radiotherapy with either 131I-mIBG 
or 177Lu DOTATATE depends on the use of nuclear medicine imaging as a predictive 
biomarker. We hypothesised that a better understanding of the tissue expression of 
molecular targets might help in patient selection for therapy, and allow optimisation of 
molecular radiotherapy in clinical practice. The recent commercial availability of monoclonal 
antibodies directed against SSTR2 and NAT for immunohistochemistry offered a way in 
which we could study target distribution in neuroblastoma tissue. The purpose of this study 
was to explore expression of NAT and SSTR2 in an unselected panel of archival tumour 
samples from patients for whom clinical prognostic factors and outcome were known, with 
the aim of using the findings to suggest potential ways in which molecular radiotherapy 
treatments might be improved. 
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Materials and methods 
 
Archived formalin fixed paraffin embedded (FFPE) neuroblastoma tissue samples, with 
associated patient clinical data including age, stage, MYCN status and survival outcome, 
were received from the Children’s Cancer and Leukaemia Group (CCLG) tissue bank. 
Immunostaining was performed on a Leica Bond-Max machine. Commercially available 
antibodies for NAT and SSTR2 were used in this study. For NAT, a monoclonal antibody was 
obtained from Merck Millipore, Billerica, Massachusetts, USA (catalogue number 
MAB5620). For SSTR2, a monoclonal antibody, UMB1, produced by Epitomics, distributed by 
Insight Biotechnology, Wembley, UK (catalogue number 3582-1 AC-0162RUO) was used. The 
antibodies underwent in house checking on control organs known to contain tissues both 
positive and negative for antigen expression. This was adrenal gland for the NAT (medulla 
positive and cortex negative) and pancreas for the SSTR2 (islets positive and exocrine tissue 
negative). 
 
The FFPE slides were baked at 60°C for 1 hour, then de-waxed and rehydrated through 
graded alcohol solution. A peroxidase block was then applied to the slide for 5 minutes. The 
primary antibody was then applied. For SSTR2 a dilution of 1:200 was applied for 15 minutes 
using heat induced epitope retrieval (HIER). For the NAT a dilution of 1:1000 was used post 
primary for 8 minutes. A polymer was applied for a further 8 minutes and diaminobenzidine 
for 10 minutes. Haematoxylin was applied for a further 5 minutes. 
 
Gains et al.                                     Immunohistochemical evaluation of molecular radiotherapy   
                                                                                 target expression in neuroblastoma tissue 
- 8 - 
 
All slides were examined by two authors (JEG and NJS), blinded at the time to information 
on stage, age and MYCN status of the patient and blinded to the results of the other 
immunostaining.  
 
The samples were categorised on morphology into differentiating, poorly differentiated and 
undifferentiated neuroblastomas according to standard criteria. Each sample was then 
semi-quantitatively scored for both of the antibodies (to NAT and SSTR2) for 
1. Percentage cells staining with the antibody (0-100%) 
2. The intensity of expression of the antibody (0-100%) 
 
These scores were estimated to the nearest 10%. A composite score for the analysis 
(ranging from 0 to 100% in steps of 5%) was derived by adding the percentage cells staining 
with the percentage intensity of expression, and dividing by two [21, 22].  
 
As the choice of cut-off points for categorising NAT and STTR2 combined scores is not clear 
in neuroblastoma, and the prognostic influence of NAT and STTR2 measures is also unclear, 
analysis of measures in their original continuous form was performed. This took values 
between 0 and 100% rather than grouping them into categories such as low, medium and 
high tertiles, because categorising a continuous measure results in loss of information and 
power. The results of immunohistochemical staining score for both NAT and SSTR2 were 
linked with known available data available from the CCLG tissue bank on age, stage, MYCN 
amplification and survival outcome.  
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Data were summarised using descriptive statistics and Pearson correlation was calculated 
for association between continuous measures. Regression and Cox proportional hazards 
models were used to compare groups (univariable and multivariable analyses) and calculate 
point estimates with corresponding 95% confidence intervals (CI) for the appropriate 
outcome measures respectively. Overall survival was calculated from the date of diagnosis 
to date of death, or censored at the date when the patient was last known to be alive for 
those patients whose death had not been reported. Functional form of independent 
variable was assessed using Martingale residuals. No adjustment for multiple testing was 
made. P-values below 0.05 were considered statistically significant. Stata v12 (StataCorp 
LLC, College Station, Texas, USA) was used for the calculations. 
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Results 
 
In total, 96 tissue samples from 88 patients were received from the CCLG tissue bank. 
Thirteen patients were excluded from the analysis – Wilms tumour (n=2), completely 
necrotic sample (n=1), normal tissue (n=4), ganglioneuroblastoma (n=4), no viable tumour 
(n=2). For five patients, two or more samples were sent, comprising in total eight additional 
samples. In these cases, the earliest tumour sample from the time of diagnosis was used for 
the statistical analysis. The cases with multiple samples are reported separately to see if 
receptor expression changed with treatment (See Table 1). 
 
Tumour samples from 75 patients were available for statistical analysis. The majority were 
poorly differentiated neuroblastoma (n=62), with the others being characterised on 
morphology as differentiating (n=10) and undifferentiated (n=3). 
 
Marked variation in expression of both targets in individual tumour samples was seen 
between patients for both the intensity and percentage expression of cells, and therefore 
the composite scores. Figure 1 illustrates the heterogeneity for SSTR2, where the observed 
values were: intensity of staining, median 60%, inter quartile range (IQR) 20% to 70%; 
proportion of cells staining, median 60%, IQR 10% to 90%; composite scores, median 55%, 
IQR 30% to 80%. Figure 2 illustrates the heterogeneity for NAT, where the observed values 
were: intensity of staining, median 30%, IQR 20% to 50%; proportion of cells staining, 
median 70%, IQR 20% to 80%; composite scores, median 45%, IQR 25% to 65%. 
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Expression of one target was weakly associated with expression of the other target. A weak 
correlation was observed between the expression of NAT and of SSTR2 composite scores, 
either when all patients were considered, or when only stage 4 patients were analysed 
separately. Figure 3 shows weak positive correlation between NAT and SSTR2 composite 
scores for all 75 patients (correlation coefficient = 0.23, p = 0.05), and Figure 4 shows that 
there was a weak positive correlation between the receptor expression composite scores 
when just those 44 patients known to have stage 4 disease were examined (correlation co-
efficient = 0.14, p = 0.36). An example of this variability of receptor expression is shown in 
Figure 5. This tumour expresses SSTR2 strongly, and NAT only weakly. 
 
Within individual tumour samples, heterogeneity of target expression was sometimes 
observed as shown in Figures 6, 7 and 8.  
 
Where multiple samples were received for the same patient, the expression of SSTR2 was 
observed to increase as the tumours changed with treatment from poorly differentiated to 
differentiated in all cases (n=5) and in four out of the five cases for NAT. The data are shown 
in Table 1. 
 
Summary statistics for SSTR2 and NAT expression composite scores are presented in Table 2 
by each baseline characteristic. No significant association between patient gender, patient 
age or tumour stage and SSTR2 and NAT expression composite scores was noted. 
 
Patients without MYCN amplification were noted to have significantly higher composite 
SSTR2 expression scores compared to patients with MYCN amplified with mean difference 
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of 23% (CI: 8% to 39%, p < 0.01) and slightly higher composite NAT expression scores, mean 
difference 10% (CI: -3% to 23, p = 0.14) than patients with MYCN amplification (Table 2).  
 
Differentiating tumours were found to have higher composite SSTR2 expression scores with 
mean difference 30% (CI: 50% to 10%, p<0.01) and higher composite NAT expression scores, 
mean difference 30% (CI: 46% to 14%, p<0.01) than patients with poorly differentiated or 
undifferentiated tumours combined (Table 2). 
 
Out of 75 patients, 26 deaths were reported. For five patients last follow up date was not 
available. Overall survival at 1 and 3 years were as follows: 86% (CI: 75% to 92%), and 67% 
(CI: 54% to 77%) respectively. There is no evidence to suggest that SSTR2 or NAT has a 
prognostic influence on overall survival with hazard ratio (HR) of 0.99 (CI: 0.98 to 1.01, p = 
0.56) and HR of 0.99 (CI: 0.97 to 1.01, p = 0.25) respectively. The conclusions were 
unchanged when adjusting for important prognostic factors.  
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Discussion 
 
There have been a number of studies exploring the relationship between laboratory 
measurements of target expression, uptake of radiopharmaceuticals measured in the 
laboratory or by imaging, and clinical outcomes, with regard to both NAT and SSTR2 in 
neuroblastoma. 
 
The majority of these have examined the mRNA levels rather than protein expression. Some 
have shown that neuroblastoma cell lines that lack the expression of NAT mRNA fail to 
accumulate mIBG [23-25], and in others the NAT mRNA level has correlated with the extent 
of mIBG uptake [25-27].  
 
A recent study has examined whether there is an association between both the tumour NAT 
mRNA and the NAT protein expression with mIBG avidity in patients with neuroblastoma 
[21]. In contrast to the previous studies, no significant correlation between NAT mRNA 
expression and mIBG uptake was found: the median NAT mRNA expression level for 19 
patients with mIBG avid tumours was 12.9% compared to 5.9% in the 8 patients with mIBG 
non-avid tumours (p=0.3). However given the relatively small sample size, the lack of 
significant correlations should not be taken as evidence that there is no correlation, as this 
study only had the power to detect strong relationships. A significant correlation between 
NAT protein expression and mIBG avidity was however apparent: the median percentage 
expression was 50% in the mIBG avid patients compared to 10% in the mIBG non-avid 
patients (p=0.03). Patients with mIBG avid tumours appeared to have higher NAT intensity 
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scores (p=0.06). Only one out of the eight mIBG non-avid tumours had a NAT protein 
expression >2. As there were patients in the study who had low NAT protein expression but 
were still mIBG avid it was suggested that tumours with low NAT expression may 
accumulate mIBG via other transporters [21]. It seems therefore that protein expression (as 
we have assessed with immunohistochemical techniques) is more likely to be a valid 
biomarker than mRNA expression, although there have been no studies examining whether 
patients with greater NAT protein expression have a better response to 131I-mIBG molecular 
radiotherapy.  
 
There has been one study, but with only five patients, which demonstrated a positive 
correlation between the protein expression of SSTR2 by IHC and mRNA of SSTR2 [28]. 
 
Previous studies have found that patients with high expression of SSTR2 mRNA had a better 
survival [28-30]. One study examined somatostatin concentrations (not SSTR2 mRNA or 
protein expression) by radioimmunoassay in 39 children, >12 months of age and with stage 
3 or 4 neuroblastoma and found that the 16 children with high somatostatin concentration 
had better survival than the 23 patients with low somatostatin concentrations (p=0.005). No 
significant correlation was observed in 15 children between receptor expression as 
determined by 111In-pentetreotide scintigraphy for SSTR2 and somatostatin concentrations 
in tumour tissue [31].  
 
A study of RT-PCR on 49 neuroblastoma samples found a wide-range of SSTR2 mRNA 
expression but it was lowest in stage 4 patients. The patients with greater SSTR2 mRNA 
expression had a better survival: approximately 90% five year overall survival compared 
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with 20% (p = 0.0005). In nine patients a good correlation between the concentration of 
SSTR2 mRNA protein expression as demonstrated by uptake on 111In-pentetreotide imaging 
was found [32]. 
 
Several studies have shown that patients with MYCN amplification have lower expression of 
SSTR2 mRNA [29, 31], and a correlation between MYCN amplification and low NAT protein 
expression has been reported [21].  Within our cohort of patients, the patients with MYCN 
amplification had significantly lower composite scores for SSTR2, but the difference seen in 
the NAT score was not significant, possibly because of small sample size.  
 
As discussed above, previous studies have used varying techniques to look for SSTR2 and 
NAT in neuroblastomas. None of the studies has correlated SSTR2 or NAT protein expression 
and survival. In terms of the relevance to functional imaging and molecular radiotherapy the 
protein expression is more relevant than the measurement of mRNA.  There have been 
studies in adult neuroendocrine tumours that have found patients, with negative octreotide 
scans, but positive mRNA [33]. Studies in neuroblastoma have found mIBG uptake in 
patients with low levels of NAT mRNA [23]. It is also well recognized that that there can be a 
poor correlation between mRNA and functional protein expression possibly due to post-
translational modification. 
 
For cases with multiple samples we found that the percentage of cells expressing NAT and 
SSTR2 increased as the tumours went became more differentiated, although the number of 
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cases with multiple samples was too few for an assessment of statistical significance. It is 
unclear from the published data whether the uptake of mIBG correlates with the 
differentiation of neuroblastoma cells. The in vitro data available has supported an increase 
in mIBG uptake after cellular differentiation [34, 35].  In contrast, the first reported in vivo 
studies, supported a correlation between higher mIBG uptake in the more undifferentiated 
neuroblastomas [36, 37]. However, this was not confirmed in an in vivo study, which 
concluded that it was impossible to make judgements about the differentiation of 
neuroblastomas depending on their mIBG uptake [38].  
 
Our conclusions, based on our own observation of a high variation in both NAT and SSTR2 
expression both within tumours and between patients, and the weak correlation between 
them, and taking into account other data reviewed here are, that as expression of the 
molecular targets at a cellular level is variable and heterogeneous: 
1 a more reliable clinical assessment of the extent of disease in individual patients may 
result from scans to demonstrate the expression of both NAT (e.g. 123I-mIBG scintigraphy 
and SPECT/CT) and SSTR2 (e.g. 68Ga-DOTATATE PET/CT), and 
2 treatment schedules incorporating either NAT-directed (e.g. 131I-mIBG) or SSTR2-
directed (e.g. 177Lu-DOTATATE) therapies may fail to target all disease. 
We hypothesise that the heterogeneity observed in target expression within individual 
patients may contribute to treatment failure in patients receiving molecular radiotherapy 
directed at a single target. We hypothesise that combined treatments directed at both NAT 
and SSTR2 may result in better coverage of tumour cells, with better clinical outcomes.  
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We recommend that future clinical trials of these therapies should have a prospective 
translational component assessing NAT and SSTR2 expression in biopsy samples, and 
correlate findings with imaging results and clinical outcomes. Laboratory studies and clinical 
trials should be designed to evaluate the hypothesis that clinical outcomes may be 
improved by combination treatments of NAT-directed and SSTR2-directed molecular 
radiotherapy. 
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Legends for Illustrations 
 
Figure 1 Histograms for SSTR2 expression in 75 patients showing distribution of (A) 
percentage intensity staining of cells, (B) percentage number of cells stained, 
and (C) composite scores. 
 
Figure 2 Histograms for NAT expression in 75 patients showing distribution of (A) 
percentage intensity staining of cells, (B) percentage number of cells stained, 
and (C) composite scores. 
 
Figure 3 Scatter plot of the composite scores for both SSTR2 and NAT in all 75 patients, 
showing weak correlation between the expression of the two receptor types. 
 
Figure 4 Scatter plot of the composite scores for both SSTR2 and NAT in stage 4 patients 
(n=44), showing weak correlation between the expression of the two receptor 
types. 
 
Figure 5 Photomicrograph of a tumour sample to show (A) intense staining with SSTR2 
(100% of cells with 100% intensity) in contrast to (b) weak staining for NAT (B) 
(30% of cells with only 20% intensity) in the same part of the tumour. 
 
Figure 6 Example of variability of staining within a tumour sample: (A) H and E stain, (B) 
NAT staining and (C) SSTR2 staining. In this case the NAT and SSTR2 staining 
showed the same pattern of distribution. 
 
Figure 7 Further illustration of variable staining pattern within a tumour: (A) H and E 
stain, (B) SSTR2 staining and (C) NAT staining. There are areas of high and low 
expression of the SSTR2 and NAT corresponding to areas of well and poorly 
differentiated neuroblastoma on H and E. 
 
Figure 8  Example heterogeneity of target expression in relation to ganglion cell 
differentiation: (A) H and E stain, (B) SSTR2 staining and (C) NAT staining. This is 
more obviously seen on the SSTR2 staining than the NAT staining. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Tables 
 
Table 1  The change in expression of NAT and SSTR2 with treatment in cases where 
multiple samples were sent. 
 
 
Patient Grade SSTR2 NAT 
  Cells  
(%) 
Intensity 
(%) 
Composite 
score (%) 
Cells 
(%) 
Intensity 
(%) 
Composite 
scores (%) 
1A PD 70 70 70 40 30 35 
1B D 100 70 85 100 50 75 
1C D 100 70 85 100 50 75 
        
2A PD 80 90 85 10 10 10 
2B PD 40 30 35 20 20 20 
2C D 100 90 95 80 20 60 
        
3A PD 90 80 85 60 20 40 
3B D 100 70 85 80 30 55 
        
4A PD 50 50 50 30 30 30 
4B D 100 90 95 90 40 65 
        
5A PD 50 50 50 90 30 60 
5B D 100 90 95 30 40 35 
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Table 2  Summary statistics of SSTR2 and NAT combined scores by each baseline 
characteristic and patients’ status.  
 
 
Baseline characteristic N % 
SSTR2 combined  
scores (%) 
(n=75) 
NAT combined  
scores (%)  
(n=75) 
Mean SD Mean SD 
Gender Male 44 59 51 32 44 25 
Female 31 41 57 31 49 26 
Age 18 month and under 35 47 53 32 47 28 
Over 18 month 39 52 55 31 45 23 
Stage I 3 4 73 20 53 28 
II 6 8 47 35 53 35 
III 6 8 75 22 42 27 
IV 44 59 52 32 45 23 
IVs 5 7 28 25 31 19 
Differentiated Differentiating 10 13 80 18 72 12 
Poorly differentiated 62 83 50 31 43 25 
Undifferentiated 3 4 30 44 27 18 
MYCN Yes 18 24 39 27 40 23 
No 48 64 62 29 50 25 
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